metabolic-dysfunction-neurodegeneration

Migration, Crosslink

📖

metabolic-dysfunction-neurodegeneration

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-metabolic-dysfunction-ne

📖 Wiki Page

mechanism3868 wordssynced 2026-04-02

Metabolic Dysfunction in Neurodegeneration: Comprehensive Mechanisms and Therapeutic Implications

Overview

Neuronal survival depends on precise metabolic control. The brain, despite comprising only about 2% of body weight, consumes approximately 20% of the body's resting metabolic energy, reflecting the extraordinary energy demands of neural signaling, maintenance, and homeostasis[@attwell2001]. Dysregulation of glucose metabolism, mitochondrial function, and nutrient sensing contributes significantly to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders[@cunnane2020]. This page explores the metabolic pathways central to neuronal health and how their dysfunction drives neurodegeneration.

The concept of metabolic dysfunction in neurodegeneration has evolved from early observations of reduced cerebral glucose uptake to a sophisticated understanding of how impaired energy metabolism intersects with protein aggregation, neuroinflammation, and synaptic failure[@sweeney2018]. This intersection represents a fundamental nexus where multiple disease mechanisms converge, making metabolic pathways attractive therapeutic targets.

Brain Energy Metabolism: Fundamentals

Overview of Cerebral Energy Consumption

...

Metabolic Dysfunction in Neurodegeneration: Comprehensive Mechanisms and Therapeutic Implications

Overview

Neuronal survival depends on precise metabolic control. The brain, despite comprising only about 2% of body weight, consumes approximately 20% of the body's resting metabolic energy, reflecting the extraordinary energy demands of neural signaling, maintenance, and homeostasis[@attwell2001]. Dysregulation of glucose metabolism, mitochondrial function, and nutrient sensing contributes significantly to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders[@cunnane2020]. This page explores the metabolic pathways central to neuronal health and how their dysfunction drives neurodegeneration.

The concept of metabolic dysfunction in neurodegeneration has evolved from early observations of reduced cerebral glucose uptake to a sophisticated understanding of how impaired energy metabolism intersects with protein aggregation, neuroinflammation, and synaptic failure[@sweeney2018]. This intersection represents a fundamental nexus where multiple disease mechanisms converge, making metabolic pathways attractive therapeutic targets.

Brain Energy Metabolism: Fundamentals

Overview of Cerebral Energy Consumption

The brain's energy demands are remarkably high and precisely regulated. Neurons, the primary computational units of the brain, maintain steep ionic gradients across their membranes through the action of Na+/K+ ATPases, consuming approximately 60-80% of cortical energy for this purpose alone[@ames2000]. Action potentials and synaptic transmission account for additional substantial energy expenditure, while baseline cellular maintenance functions consume the remainder.

This high metabolic demand requires continuous and reliable energy supply, primarily in the form of adenosine triphosphate (ATP) generated through oxidative phosphorylation in mitochondria. However, neurons cannot store significant energy reserves, making them dependent on continuous blood-borne glucose delivery[@van2016]. This metabolic vulnerability underlies the brain's sensitivity to hypoxia, hypoglycemia, and mitochondrial dysfunction.

Glucose Metabolism Pathways

Glycolysis

Glycolysis converts glucose to pyruvate through a series of ten enzymatic reactions, generating a net of 2 ATP molecules per glucose molecule[@mergenthaler2013]. While inefficient compared to oxidative phosphorylation, glycolysis serves critical functions:

Rapid ATP generation: Glycolysis can produce ATP quickly when needed
Biosynthetic precursors: Metabolic intermediates feed into biosynthetic pathways
Oxygen-independent operation: Can function under hypoxic conditions
Pentose phosphate pathway branch: Provides NADPH and ribose for biosynthesis

In neurons, glycolysis is particularly important because mitochondria in neurons are more prone to releasing cytochrome c and triggering apoptosis compared to other cell types[@nicholls2009]. This makes neurons partially dependent on glycolytic ATP for survival.

Tricarboxylic Acid Cycle

The tricarboxylic acid (TCA) cycle, also known as the Krebs cycle or citric acid cycle, completes the oxidation of glucose-derived pyruvate, generating:

2 ATP equivalents (GTP) per glucose
6 NADH and 2 FADH2 for oxidative phosphorylation
Metabolic intermediates for biosynthesis

The TCA cycle operates in the mitochondrial matrix and requires continuous supply of acetyl-CoA from pyruvate, fatty acids, or amino acids[@shulman2020]. Key regulatory points include:

Citrate synthase: Primary regulatory enzyme
Isocitrate dehydrogenase: NAD+-dependent, sensitive to ATP/ADP ratio
α-ketoglutarate dehydrogenase: Rate-limiting, sensitive to NADH

Oxidative Phosphorylation

Oxidative phosphorylation couples the oxidation of NADH and FADH2 to ATP synthesis through the electron transport chain (ETC)[@saraste1999]. The ETC comprises four complexes (I-IV) that sequentially transfer electrons from donors to oxygen, creating a proton gradient across the inner mitochondrial membrane. Complex V (ATP synthase) uses this gradient to synthesize ATP.

In neurons, oxidative phosphorylation primarily occurs in dendrites and near synapses, where energy demands are highest[@kann2006]. Mitochondrial distribution and dynamics (fusion/fission) are carefully regulated to meet these spatially heterogeneous demands.

Astrocyte-Neuron Metabolic Coupling

The traditional view of brain energy metabolism as neuron-centric has evolved to recognize the critical role of astrocytes, a major class of glial cells[@pellerin1994]. This metabolic partnership involves several key processes:

Glycogen Metabolism

Astrocytes, but not neurons, store glycogen—the largest energy reserve in the brain[@brown2004]. Glycogenolysis can provide rapid energy during:

Sustained neuronal activity
Hypoglycemia
Ischemia

Astrocyte glycogen is metabolized to lactate, which is then shuttled to neurons as an alternative fuel.

Lactate Shuttle Hypothesis

The lactate shuttle hypothesis proposes that astrocyte-derived lactate serves as a primary energy substrate for active neurons[@van2015]. According to this model:

Neuronal activity increases glutamate release

Glutamate uptake by astrocytes stimulates glycolysis

Lactate is released by astrocytes and taken up by neurons

Neurons oxidize lactate to meet increased energy demands

This coupling ensures that energy supply matches demand across the neurovascular unit.

Glutamate-Glutamine Cycle

Glutamate, the primary excitatory neurotransmitter, is recycled through the glutamate-glutamine cycle[@hertz2009]. This process:

Removes extracellular glutamate (preventing excitotoxicity)
Provides metabolic energy for astrocytes
Couples neurotransmitter recycling to cellular metabolism

For each glutamate molecule recycled, astrocytes expend approximately 1 ATP, linking neurotransmitter cycling directly to cellular energetics.

Glucose Hypometabolism in Alzheimer's Disease

Evidence from Neuroimaging

FDG-PET Studies

Fluorodeoxyglucose positron emission tomography (FDG-PET) has established cerebral glucose hypometabolism as a hallmark of Alzheimer's disease[@mosconi2005]. Characteristic patterns include:

Early/Prodromal AD:

Posterior cingulate cortex hypometabolism (earliest consistent finding)
Hippocampal and entorhinal cortex hypometabolism
Precuneus involvement

Established AD:

Progressive hypometabolism extending to lateral parietal cortex
Temporal lobe involvement
Relative preservation of primary sensory and motor cortices
Later involvement of frontal regions

These hypometabolic patterns correlate with clinical severity and precede clinical symptoms in at-risk individuals by years to decades[@jack2010].

Longitudinal Studies

Longitudinal FDG-PET studies reveal:

Hypometabolism progresses in a characteristic pattern matching neurofibrillary tangle distribution
Rate of hypometabolism predicts clinical progression
Metabolic decline precedes structural atrophy in many cases

Mechanisms of Hypometabolism

Insulin Resistance

Brain insulin resistance has emerged as a central mechanism in AD pathophysiology[@arnold2018]. The brain is an insulin-sensitive organ with widespread insulin receptor expression, particularly in the hippocampus, cerebral cortex, and cerebellum. Insulin signaling in the brain regulates:

Synaptic plasticity and memory formation
Glucose uptake and metabolism
Neuronal survival
Amyloid and tau metabolism

In AD brain, evidence of insulin resistance includes:

Reduced IRS-1 (insulin receptor substrate 1) tyrosine phosphorylation
Increased serine phosphorylation of IRS-1 (inhibitory)
Decreased downstream PI3K/Akt signaling
Altered expression of glucose transporters

This "type 3 diabetes" hypothesis proposes that brain insulin resistance contributes to AD pathogenesis through multiple pathways[@de2008].

Mitochondrial Dysfunction

Mitochondrial abnormalities are prominent in AD[@swerdlow2002]:

Reduced Complex IV activity
Increased mitochondrial DNA mutations
Impaired calcium handling
Reduced ATP production
Enhanced reactive oxygen species (ROS) generation

Amyloid-beta (Aβ) directly interacts with mitochondria, impairing function, while tau pathology disrupts mitochondrial transport and distribution within neurons[@manczak2006].

Amyloid Interference with Glucose Metabolism

Aβ oligomers and aggregates interfere with multiple aspects of glucose metabolism[@sheng2012]:

GLUT trafficking: Aβ reduces GLUT3 and GLUT4 translocation
Glycolytic enzymes: Aβ inhibits key glycolytic steps
Mitochondrial function: Direct binding and functional impairment
Insulin signaling: Aβ disrupts insulin receptor function

Glutamate Toxicity

Excessive glutamate stimulation consumes ATP through:

Na+/K+ ATPase activation to restore ion gradients
Increased metabolic demand for restored homeostasis
Possible uncpling of mitochondrial function

This creates a vicious cycle where excitotoxicity impairs metabolism, and impaired metabolism reduces the brain's capacity to handle glutamate[@alano2010].

Therapeutic Implications

Understanding glucose hypometabolism has led to therapeutic strategies:

Intranasal Insulin:

Delivers insulin directly to the brain
Improves memory in AD and MCI patients
Phase II trials showing promise[@craft2012]

Insulin Sensitizers:

Metformin: Mixed results in clinical trials
Thiazolidinediones: PPARγ agonists under investigation

Glucose Transport Enhancement:

Targeting GLUT1/GLUT3 expression
Small molecule GLUT activators in development

Metabolic Dysfunction in Parkinson's Disease

Brain Glucose Metabolism in PD

Nigrostriatal Hypometabolism

Early studies using FDG-PET revealed characteristic hypometabolism in the basal ganglia of PD patients[@eidelberg1995]:

Posterior putamen (contralateral to most affected side)
Caudate nucleus
Midbrain (including substantia nigra)

This hypometabolism reflects:

Dopaminergic neuron loss
Reduced metabolic demand of denervated striatum
Secondary effects on basal ganglia circuitry

Cortical Hypometabolism

As PD progresses, cortical hypometabolism develops:

Premotor cortex
Posterior parietal cortex
Occipital cortex (especially visual cortex)

This pattern correlates with:

Disease duration
Cognitive impairment
Development of Parkinson's disease dementia

Mitochondrial Complex I Deficiency

The most consistent biochemical abnormality in PD is reduced activity of mitochondrial Complex I[@schapira2007]. Evidence includes:

Reduced Complex I activity in substantia nigra
Decreased Complex I subunit expression
Impaired Complex I assembly

This deficiency:

Reduces ATP production
Increases ROS generation
Promotes neuronal death
May relate to environmental toxin sensitivity

Systemic Metabolic Abnormalities

Type 2 Diabetes and PD Risk

Epidemiological studies consistently show that type 2 diabetes increases PD risk by 20-40%[@hu2007]. Shared features include:

Insulin resistance
Mitochondrial dysfunction
Chronic inflammation

This association suggests common metabolic pathways may underlie both conditions.

Other Systemic Markers

PD patients often show:

Altered fasting glucose levels
Dyslipidemia
Altered adipokine levels
Changed gut microbiome (affecting metabolism)

These systemic changes may reflect:

Subclinical metabolic dysfunction
Effects of chronic dopaminergic therapy
Disease-related autonomic changes

Therapeutic Implications

Metabolic approaches to PD include:

Mitochondrial Protectants:

Coenzyme Q10: Mixed trial results
Creatine: Under investigation
Mitochondrial-targeted antioxidants

Metformin:

May reduce PD risk in diabetics
Potential neuroprotective effects
Clinical trials ongoing

Ketogenic Approaches:

May support neuronal metabolism
May reduce motor symptoms
Limited but promising data

Ketone Metabolism and Alternative Fuels

Ketone Bodies as Alternative Fuel

When glucose availability is limited (fasting, ketogenic diet), the liver produces ketone bodies—beta-hydroxybutyrate and acetoacetate—which can serve as alternative fuel for the brain[@veech2004]. Ketone metabolism offers several advantages:

Advantages of Ketone Metabolism

Reduced ROS generation: Ketone oxidation produces fewer reactive oxygen species than glucose
Improved mitochondrial efficiency: Ketone oxidation may be more efficient
Alternative energy substrate: Bypasses impaired glucose metabolism
Signaling functions: Ketone bodies have signaling properties beyond metabolism

Brain Ketone Uptake

Ketone bodies enter the brain via monocarboxylate transporters (MCTs)[@pierre2005]:

MCT1: Endothelial cells of blood-brain barrier
MCT2: Neuronal expression
MCT4: Astrocyte expression

Expression and activity of these transporters can limit brain ketone uptake, particularly in aging.

Ketogenic Diet in Neurodegeneration

The ketogenic diet, high in fat and low in carbohydrates, induces ketogenesis and has been studied in neurodegenerative diseases[@broom2019].

Mechanisms of Benefit

Direct metabolic effects:

Improved mitochondrial function
Reduced oxidative stress
Enhanced energy efficiency

Signaling effects:

Increased GABA (reducing excitotoxicity)
Enhanced BDNF expression
Activated anti-inflammatory pathways

Protein homeostasis:

Enhanced autophagy
Improved proteostasis

Clinical Evidence

Alzheimer's Disease:

Ketogenic diet improves cognition in mild cognitive impairment[@krikorian2012]
Ketone supplementation (MCT) shows cognitive benefits
Larger trials ongoing

Parkinson's Disease:

Ketogenic diet may improve motor symptoms[@phillips2018]
Limited but encouraging data

Ketone Supplements

Exogenous ketone supplements offer a less restrictive approach[@newport2015]:

Beta-hydroxybutyrate salts
Ketone esters
Medium-chain triglyceride (MCT) oil

These can elevate circulating ketone levels without requiring strict dietary adherence.

Lipid Metabolism in Neurodegeneration

Lipid Dysregulation in AD

The brain is rich in lipids, which are essential for:

Membrane structure
Myelin formation
Synaptic function
Signaling molecules

AD is associated with widespread lipid dysregulation[@chang2017]:

Cholesterol

Brain cholesterol metabolism is altered in AD:

Reduced cholesterol synthesis
Altered ApoE-mediated transport
Relationship between cholesterol and amyloid processing

Sphingolipids

Ceramide accumulation is a consistent finding in AD[@cutler2004]:

Promotes neuronal apoptosis
Enhances amyloid toxicity
Activates inflammatory pathways

Phospholipids

Membrane phospholipid alterations include:

Reduced phosphatidylcholine
Altered phosphatidylserine
Changed polyunsaturated fatty acid levels

ApoE and Lipid Transport

Apolipoprotein E (ApoE) plays critical roles in brain lipid transport[@huang2012]:

ApoE isoforms:

ApoE3: Most common, neutral risk
ApoE4: Major genetic risk factor for AD
ApoE2: May be protective

Functions:

Cholesterol and phospholipid transport
Amyloid clearance
Synaptic repair and plasticity
Neuroinflammation modulation

ApoE4 effects:

Impaired lipid transport
Reduced amyloid clearance
Enhanced neuroinflammation
Synaptic dysfunction

Amino Acid Metabolism

Glutamate/GABA Balance

The balance between excitatory (glutamate) and inhibitory (GABA) neurotransmission is fundamental to brain function and highly metabolically demanding[@schousboe2005].

Excitotoxicity

Excessive glutamate leads to:

Calcium influx through NMDA receptors
Mitochondrial overload
ROS generation
Activation of apoptotic pathways

Neuronal energy failure impairs the ability to maintain glutamate homeostasis, creating a vicious cycle[@choi2003].

Energy Failure Compensation

When energy is limited, neurons cannot maintain ion gradients, leading to:

Depolarization (reducing the gradient for glutamate uptake)
Release of glutamate
Further activation of excitotoxic pathways

Tryptophan Metabolism

Tryptophan metabolism through the kynurenine pathway produces neuroactive metabolites[@schwarcz2012]:

Quinolinic acid: NMDA agonist, neurotoxic
Kynurenic acid: NMDA antagonist, neuroprotective

In neurodegenerative diseases:

Increased quinolinic acid
Elevated quinolinic/kynurenic acid ratio
Potential for neurotoxicity

Therapeutic Approaches

Metabolic Enhancers

Exercise

Exercise enhances brain metabolism through[@cotman2007]:

Increased cerebral blood flow
Elevated growth factor expression (BDNF, IGF-1)
Enhanced mitochondrial biogenesis
Improved insulin sensitivity

Regular exercise is associated with reduced AD risk and may slow progression.

Caloric Restriction

Caloric restriction extends lifespan and may improve brain health[@mattson2005]:

Enhanced autophagy
Reduced oxidative stress
Improved metabolic health
Increased neurotrophic factor expression

Dietary Interventions

Mediterranean diet: Associated with reduced AD risk
MIND diet: Specifically designed for brain health
Time-restricted eating: Metabolic benefits

Pharmacological Approaches

Metformin:

Improves insulin sensitivity
May reduce dementia risk in diabetics
Clinical trial results mixed

Targeted Antioxidants:

Coenzyme Q10
Alpha-lipoic acid
Vitamin E

Mitochondrial Modulators:

Pioglitazone (PPARγ agonist)
Mitochondrial-targeted peptides

Future Directions

Metabolic therapies for neurodegeneration are evolving toward:

Personalized approaches: Based on metabolic phenotype

Combination therapies: Targeting multiple metabolic pathways

Biomarker development: Identifying patients most likely to benefit

Early intervention: Treating before irreversible damage

Cross-Disease Comparison Matrix

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|---------------------|
| Primary Metabolic Alteration | Glucose hypometabolism, insulin resistance | Glucose hypometabolism, mitochondrial dysfunction | Metabolic inflexibility, glycolytic shift | Glucose dysregulation, altered energy expenditure | Metabolic hyperactivity, increased energy expenditure |
| Key Enzymes Affected | IDHK, PDH, complex IV | Complex I, IDH, α-KGDH | Glycolytic enzymes, IDH | Various metabolic enzymes | IDH, metabolic enzymes |
| Brain Region Affected | Hippocampus, entorhinal cortex | Substantia nigra, striatum | Motor cortex, spinal cord | Frontal, temporal lobes | Striatum, cortex |
| Energy Crisis | Severe in early disease | Moderate, progressive | Severe in later stages | Variable | Progressive |
| Therapeutic Target | Ketogenic diet, metabolic modulators | Metabolic enhancers, CoQ10 | Metabolic support | Metabolic modulators | Metabolic inhibitors |

Mechanisms of Metabolic Dysfunction Across Diseases

Amyotrophic Lateral Sclerosis

ALS exhibits metabolic inflexibility with a shift toward glycolytic metabolism. Patients often show hypermetabolism despite weight loss, indicating increased energy expenditure. Motor neurons are particularly vulnerable due to their large size and high metabolic demands.

Hypermetabolism in ALS: ALS patients exhibit resting energy expenditure approximately 15-25% higher than predicted based on body composition. This hypermetabolic state persists throughout disease progression and is independent of disease stage, respiratory function, or inflammatory markers. The hypermetabolic state creates a catabolic environment where patients lose weight despite adequate caloric intake. Weight loss, particularly loss of lean body mass, correlates with reduced survival and faster disease progression.

Motor Neuron Energy Demands: Motor neurons represent the largest cells in the central nervous system, with some extending axons over one meter in length. This extreme morphology creates unique metabolic challenges including continuous Na+/K+ ATPase activity and enormous energetic cost of action potential propagation.

Glycolytic Shift and Lactate Dynamics: ALS motor neurons exhibit a metabolic shift toward glycolysis, reflected by elevated lactate levels in the cerebrospinal fluid. This shift may represent an attempt to maintain ATP production despite impaired oxidative phosphorylation. However, glycolysis generates only 2 ATP per glucose molecule compared to 36 from complete oxidation.

Frontotemporal Dementia

FTD shows variable metabolic patterns depending on the subtype. Both hypometabolism and regional-specific metabolic changes have been documented.

Subtype-Specific Patterns: The three major FTD subtypes — behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and logopenic variant primary progressive aphasia (lvPPA) — exhibit distinct metabolic patterns on FDG-PET. bvFTD shows predominant frontal and anterior cingulate hypometabolism; svPPA demonstrates focal anterior temporal lobe hypometabolism; lvPPA shows left temporoparietal hypometabolism similar to typical AD.

Glucose Transporter Dysfunction: GLUT1 and GLUT3 dysfunction can impair glucose uptake and contribute to hypometabolism in FTD.

Relationship to Mitochondrial Dysfunction: Mitochondrial dysfunction is prominent in FTD, particularly in cases with tau pathology. The 4-repeat tau isoforms characteristic of CBD and PSP are associated with mitochondrial deficits. Tau directly interacts with mitochondria, impairing complex V activity and reducing ATP production.

Huntington's Disease

HD shows a paradoxical pattern of hypermetabolism despite progressive neurodegeneration. Patients exhibit increased energy expenditure and catabolism, leading to weight loss despite adequate caloric intake.

Mutant Huntingtin and Metabolic Dysfunction: The mutant huntingtin (mHtt) protein directly impairs cellular metabolism through multiple mechanisms. mHtt interacts with mitochondria, disrupting dynamics, transport, and function. Additionally, mHtt alters the expression of PGC-1α, a master regulator of mitochondrial biogenesis.

Hypermetabolism and Catabolism: HD patients exhibit resting energy expenditure approximately 20-30% higher than matched controls, despite reduced physical activity. Weight loss, particularly loss of fat-free mass, correlates with faster disease progression and reduced survival.

Advanced Therapeutic Strategies

Metabolic Modulation Approaches

Targeting metabolic pathways offers disease-modifying potential across neurodegenerative conditions. Several strategies show promise based on underlying mechanisms:

Ketogenic Diet Interventions

Provides alternative fuel via ketone bodies
Bypasses impaired glucose metabolism
Shown benefit in AD, PD, and ALS models
Human trials ongoing for all three conditions

Mitochondrial Biogenesis Enhancement

PGC-1α activation through exercise or pharmacologic agents
TFAM upregulation for mitochondrial DNA replication
NAD+ precursors to enhance sirtuin activity

Metabolic Flexibility Restoration

Targeting insulin signaling pathways
AMPK activators to enhance cellular energy sensing
mTOR inhibition to promote autophagy

Advanced Clinical Trial Landscape

| Agent | Target | Disease | Phase | Status |
|-------|--------|---------|-------|--------|
| Pioglitazone | PPAR-γ | AD | 3 | Active |
| CoQ10 | Mitochondria | PD | 3 | Completed |
| Creatine | ATP | PD/ALS | 3 | Completed |
| Ketone esters | Metabolism | AD/PD | 2 | Active |

Metabolic Dysfunction Pathway Diagram

Mermaid diagram (expand to render)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[Insulin Signaling in AD](/mechanisms/insulin-signaling-ad)
[Ketogenic Diet in Neurodegeneration](/therapeutics/ketogenic-diet-neurodegeneration)
[Adult Hippocampal Neurogenesis](/mechanisms/neurogenesis-ad-superagers)
[Neuroinflammation](/mechanisms/neuroinflammation)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Attwell D, Laughlin SB, An energy budget for signaling in the grey matter of the brain (2001)](https://pubmed.ncbi.nlm.nih.gov/11706622/)

[Cunnane SC, Trushina E, Morland C, et al, Brain glucose metabolism in health, aging, and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32241993/)

[Sweeney MD, Sagare AP, Zlokovic BV, Blood-brain barrier breakdown in Alzheimer's disease and other neurodegenerative disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29198525/)

[Ames A 3rd, CNS energy metabolism as related to function (2000)](https://pubmed.ncbi.nlm.nih.gov/10818012/)

[van de Haar HJ, Jansen JFA, van Osch MJ, et al, Neurovascular unit imaging: a framework for studying physiological adaptations and pathological changes in the cerebral vasculature (2016)](https://pubmed.ncbi.nlm.nih.gov/27297157/)

[Mergenthaler P, Lindauer U, Dienel GA, et al, Sugar for the brain: the role of glucose in physiological and pathological brain function (2013)](https://pubmed.ncbi.nlm.nih.gov/23959284/)

[Nicholls DG, Mitochondrial calcium function and dysfunction in the central nervous system (2009)](https://pubmed.ncbi.nlm.nih.gov/15852472/)

[Shulman RG, Hyder F, Rothman DL, Cerebral metabolism and the emergent function of neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/12006668/)

[Saraste M, Oxidative phosphorylation at the fin de siècle (1999)](https://pubmed.ncbi.nlm.nih.gov/10604464/)

[Kann O, Kuhlkamp T, Engelmann LC, et al, Voltage-gated Ca2+ currents and their mitochondrial contribution in the presynaptic nerve terminal (2006)](https://pubmed.ncbi.nlm.nih.gov/16803845/)

[Pellerin L, Magistretti PJ, Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization (1994)](https://pubmed.ncbi.nlm.nih.gov/7961915/)

[Brown AM, Brain glycogen re-awakened (2004)](https://pubmed.ncbi.nlm.nih.gov/15576002/)

[van den Heuvel MP, Kandel ER, Brain networks, from neurons to societies (2015)](https://pubmed.ncbi.nlm.nih.gov/25937356/)

[Hertz L, The glutamate-GABA-glutamine cycle: an overview, with emphasis on the role of glutamate in GABA synthesis and removal (2009)](https://pubmed.ncbi.nlm.nih.gov/19818465/)

[Mosconi L, Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15602730/)

[Jack CR Jr, Knopman DS, Jagust WJ, et al, Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010)](https://pubmed.ncbi.nlm.nih.gov/20083042/)

[Arnold SE, Arvanitakis Z, Macauley-Rambach SL, et al, Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums (2018)](https://pubmed.ncbi.nlm.nih.gov/29566779/)

[de la Monte SM, Wands JR, Alzheimer's disease is type 3 diabetes-evidence reviewed (2008)](https://pubmed.ncbi.nlm.nih.gov/19013169/)

[Swerdlow RH, Kish SJ, Mitochondria in Alzheimer's disease (2002)](https://pubmed.ncbi.nlm.nih.gov/12445501/)

[Manczak M, Anekonda TS, Henson E, et al, Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression (2006)](https://pubmed.ncbi.nlm.nih.gov/16505187/)

[Sheng B, Wang X, Su B, et al, Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22705714/)

[Alano CC, Garnier P, Ying W, et al, NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death (2010)](https://pubmed.ncbi.nlm.nih.gov/20482438/)

[Craft S, Baker LD, Montine TJ, et al, Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial (2012)](https://pubmed.ncbi.nlm.nih.gov/22037104/)

[Eidelberg D, Takikawa S, Moeller JR, et al, The metabolic topography of Parkinsonism (1995)](https://pubmed.ncbi.nlm.nih.gov/7885465/)

[Schapira AH, Mitochondrial dysfunction in Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/16128461/)

[Hu G, Jousilahti P, Bidel S, et al, Type 2 diabetes and the risk of Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17460449/)

[Veech RL, The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism (2004)](https://pubmed.ncbi.nlm.nih.gov/15055346/)

[Pierre K, Pellerin L, Monocarboxylate transporters in the central nervous system: distribution, regulation and function (2005)](https://pubmed.ncbi.nlm.nih.gov/15620683/)

[Broom GM, Shaw IC, Rucklidge JJ, The ketogenic diet as a potential treatment for Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30763158/)

[Krikorian R, Shidler MD, Dangelo K, et al, Dietary ketosis improves memory in mild cognitive impairment (2012)](https://pubmed.ncbi.nlm.nih.gov/22170357/)

[Phillips MCL, Murtagh DKJ, Gilbertson LJ, et al, Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial (2018)](https://pubmed.ncbi.nlm.nih.gov/30149876/)

[Newport MT, VanItallie TB, Kashiwaya Y, et al, A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25499957/)

[Chang TY, Yamauchi Y, Hasan MT, et al, Cellular cholesterol homeostasis and Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28456780/)

[Cutler RG, Kelly J, Storie K, et al, Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease (2004)](https://pubmed.ncbi.nlm.nih.gov/14749433/)

[Huang Y, Mucke L, Alzheimer mechanisms and therapeutic strategies (2012)](https://pubmed.ncbi.nlm.nih.gov/22940876/)

[Schousboe A, Waagepetersen HS, Role of astrocytes in glutamate homeostasis: implications for excitotoxicity (2005)](https://pubmed.ncbi.nlm.nih.gov/15935491/)

[Choi DW, Excitotoxicity (2003)](https://pubmed.ncbi.nlm.nih.gov/14578017/)

[Schwarcz R, Bruno JP, Muchowski PJ, et al, Kynurenines in the mammalian brain: when physiology meets pathology (2012)](https://pubmed.ncbi.nlm.nih.gov/22727062/)

[Cotman CW, Berchtold NC, Christie LA, Exercise builds brain health: key roles of growth factor cascades and inflammation (2007)](https://pubmed.ncbi.nlm.nih.gov/17884808/)

[Mattson MP, Energy intake, meal frequency, and health: a neurobiological perspective (2005)](https://pubmed.ncbi.nlm.nih.gov/15860453/)

📖 View canonical wiki page →

Related Entities

mechanisms-metabolic-dysfunction-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-metabolic-dysfunction-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4779400fc90e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-metabolic-dysfunction-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

557

Outgoing

732

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

metabolic-dysfunction-neurodegeneration

Metabolic Dysfunction in Neurodegeneration: Comprehensive Mechanisms and Therapeutic Implications

Overview

Brain Energy Metabolism: Fundamentals

Overview of Cerebral Energy Consumption

Metabolic Dysfunction in Neurodegeneration: Comprehensive Mechanisms and Therapeutic Implications

Overview

Brain Energy Metabolism: Fundamentals

Overview of Cerebral Energy Consumption

Glucose Metabolism Pathways

Glycolysis

Tricarboxylic Acid Cycle

Oxidative Phosphorylation

Astrocyte-Neuron Metabolic Coupling

Glycogen Metabolism

Lactate Shuttle Hypothesis

Glutamate-Glutamine Cycle

Glucose Hypometabolism in Alzheimer's Disease

Evidence from Neuroimaging

FDG-PET Studies

Longitudinal Studies

Mechanisms of Hypometabolism

Insulin Resistance

Mitochondrial Dysfunction

Amyloid Interference with Glucose Metabolism

Glutamate Toxicity

Therapeutic Implications

Metabolic Dysfunction in Parkinson's Disease

Brain Glucose Metabolism in PD

Nigrostriatal Hypometabolism

Cortical Hypometabolism

Mitochondrial Complex I Deficiency

Systemic Metabolic Abnormalities

Type 2 Diabetes and PD Risk

Other Systemic Markers

Therapeutic Implications

Ketone Metabolism and Alternative Fuels

Ketone Bodies as Alternative Fuel

Advantages of Ketone Metabolism

Brain Ketone Uptake

Ketogenic Diet in Neurodegeneration

Mechanisms of Benefit

Clinical Evidence

Ketone Supplements

Lipid Metabolism in Neurodegeneration

Lipid Dysregulation in AD

Cholesterol

Sphingolipids

Phospholipids

ApoE and Lipid Transport

Amino Acid Metabolism

Glutamate/GABA Balance

Excitotoxicity

Energy Failure Compensation

Tryptophan Metabolism

Therapeutic Approaches

Metabolic Enhancers

Exercise

Caloric Restriction

Dietary Interventions

Pharmacological Approaches

Future Directions

Cross-Disease Comparison Matrix

Mechanisms of Metabolic Dysfunction Across Diseases

Amyotrophic Lateral Sclerosis

Frontotemporal Dementia

Huntington's Disease

Advanced Therapeutic Strategies

Metabolic Modulation Approaches

Advanced Clinical Trial Landscape

Metabolic Dysfunction Pathway Diagram

Cross-Links to Related Pages

See Also

External Links

References

💬 Discussion